Use of a Healthcare Claims Database for Post-Marketing Safety Assessments of Eribulin in Japan: A Comparative Assessment with a Prospective Post-Marketing Surveillance Study

• Main Authors: Yukinori Sakata (Author), Toshiyuki Matsuoka (Author), Satoshi Ohashi (Author), Tadashi Koga (Author), Tetsumi Toyoda (Author), Mika Ishii (Author)
• Format: Book
• Published: Adis, Springer Healthcare, 2019-03-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.

Abstract Background To understand the extent to which a large-scale healthcare claims database (DB) captures the safety profile of eribulin mesylate (Halaven®, Eisai Co., Ltd., Japan), we compared patient characteristics, drug use, and adverse events (AEs) between data for patients treated with erib...